Physician profile
Rachel N Shell
NPI 1942339932
$454.60
in general payments reported to CMS, 2019-2025
16 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $234 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $67.32 | 2023-2025 | Omnipod |
| Medtronic, INC. | $49.10 | 2023-2025 | Minimed 780g |
| Beta Bionics, INC. | $38.24 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amphastar Pharmaceuticals, INC. | $37.97 | 2024-2025 | |
| Amgen INC. | $31.52 | 2023-2025 | Prolia, Evenity, Tepezza |
| Novartis Pharmaceuticals Corporation | $31.10 | 2024 | |
| Dexcom, INC. | $24.98 | 2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $23.52 | 2024 | Unithroid |
| Ascensia Diabetes Care US INC. | $22.42 | 2025 | |
| Esperion Therapeutics, INC. | $21.09 | 2024 | Nexletol |
| Novo Nordisk INC | $20.38 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $19.54 | 2023 | |
| Lilly USA, LLC | $19.00 | 2024 | Zepbound |
| Horizon Therapeutics Plc | $16.63 | 2023 | Tepezza |
| Lexicon Pharmaceuticals, INC. | $16.54 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $15.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.